Skip to content
CancerIndex

Publication

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

Authors not recorded

Haematologica2010PMID 20494930PMC2948091stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (3)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 3

Curated evidence

Evidence citing this paper (1)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
20494930
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
IDH1 R1321
(prognostic)Myelodysplastic SyndromeCURATED_BROADERPrognosticBSupports Poor Outcome4accepted
EID374

IDH1 R132 mutation in patients suffering from myelodysplastic syndromes is associated with worse overall survival.

PMID 20494930 · Thol et al., 2010 · Open in CIViC

civic